TESARO, Inc. (NASDAQ:TSRO) Director James O. Armitage sold 10,000 shares of the firm’s stock in a transaction dated Monday, September 18th. The shares were sold at an average price of $117.13, for a total value of $1,171,300.00. Following the completion of the sale, the director now directly owns 10,000 shares in the company, valued at approximately $1,171,300. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

TESARO, Inc. (NASDAQ:TSRO) opened at 119.04 on Friday. TESARO, Inc. has a 52 week low of $96.52 and a 52 week high of $192.94. The stock’s market capitalization is $6.45 billion. The firm has a 50-day moving average price of $121.03 and a 200-day moving average price of $138.94.

TESARO (NASDAQ:TSRO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.52) by ($0.30). TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The company had revenue of $29.50 million for the quarter, compared to analysts’ expectations of $18.61 million. During the same quarter last year, the company earned ($1.28) earnings per share. The company’s revenue for the quarter was down 17.6% on a year-over-year basis. Equities research analysts predict that TESARO, Inc. will post ($8.61) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/23/tesaro-inc-tsro-director-sells-1171300-00-in-stock.html.

A number of hedge funds have recently modified their holdings of TSRO. BlackRock Inc. raised its position in TESARO by 4,504.8% during the first quarter. BlackRock Inc. now owns 3,409,657 shares of the biopharmaceutical company’s stock valued at $524,643,000 after purchasing an additional 3,335,611 shares during the period. Janus Henderson Group PLC purchased a new stake in TESARO during the second quarter valued at approximately $100,301,000. PointState Capital LP purchased a new stake in TESARO during the second quarter valued at approximately $85,971,000. TIAA CREF Investment Management LLC raised its position in TESARO by 167.9% during the first quarter. TIAA CREF Investment Management LLC now owns 367,519 shares of the biopharmaceutical company’s stock valued at $56,550,000 after purchasing an additional 230,353 shares during the period. Finally, Pioneer Investment Management Inc. raised its position in TESARO by 195.6% during the second quarter. Pioneer Investment Management Inc. now owns 317,753 shares of the biopharmaceutical company’s stock valued at $44,441,000 after purchasing an additional 210,273 shares during the period.

Several analysts have weighed in on TSRO shares. ValuEngine raised TESARO from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Oppenheimer Holdings, Inc. set a $199.00 price target on TESARO and gave the company a “buy” rating in a report on Sunday, June 4th. Cann reaffirmed a “buy” rating and issued a $199.00 price target on shares of TESARO in a report on Monday, June 5th. FBR & Co lowered their price target on TESARO from $200.00 to $195.00 and set a “mkt perform” rating on the stock in a report on Monday, June 5th. Finally, Wedbush raised TESARO to an “outperform” rating and set a $168.00 price objective on the stock in a report on Monday, June 5th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $171.42.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Insider Buying and Selling by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.